Date: November 8, 2021
Your Name: Haobo Li
Manuscript Title: Backhanded Complement: Circulating Exosomes in Aged Animals Add Insult to Injury After Stroke
Manuscript number (if known): ExRNA-21-21

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	American Heart Association (20CDA35310184)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	lectures, presentations, speakers bureaus,	_X_None
	manuscript writing or educational events	
6	Payment for expert testimony	_X_None
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or pending	_X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None
11	Stock or stock options	_X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None
13	Other financial or non- financial interests	_X_None

HL was supported by the American Heart Association (20CDA3531018	34).

Please place an "X" next to the following statement to indicate your agreement:

Date: November 8, 2021
Your Name: Cedric Sheffield Jr
Manuscript Title: Backhanded Complement: Circulating Exosomes in Aged Animals Add Insult to Injury After Stroke
Manuscript number (if known): ExRNA-21-21

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Sarnoff Cardiovascular Research Foundation	
2	Grants or contracts from	Time frame: past _X_None	36 months
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_X_None	
	financial interests		

CDS was supported by the Sarnoff Cardiovascular Research Foundation.

Please place an "X" next to the following statement to indicate your agreement:

Date: November 8, 2021
Your Name: J. Sawalla Guseh
Manuscript Title: Backhanded Complement: Circulating Exosomes in Aged Animals Add Insult to Injury After Stroke
Manuscript number (if known): ExRNA-21-21

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	American Heart Association (19AMFDP34990046) Massachusetts General Hospital Sanchez Fegoson Faculty Scholar Program	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past _X_None _X_None	36 months
4	Consulting fees	_X_None	

_			
5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
	3.1.1,		
8	Patents planned, issued or	_X_None	
	pending		
	_		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services	<u> </u>	
13	Other financial or non-	_X_None	
	financial interests		

JSG was supported by the American Heart Association (19AMFDP34990046) and Massachusetts General Hospital Sanchez Fegoson Faculty Scholar Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: November 8, 2021
Your Name: Anthony Rosenzweig
Manuscript Title: Backhanded Complement: Circulating Exosomes in Aged Animals Add Insult to Injury After Stroke
Manuscript number (if known): ExRNA-21-21

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Institutes of Health (R01AG061034) National Institutes of Health (R35HL155318)			
	36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None			
3	Royalties or licenses	_X_None			
4	Consulting fees	_X_None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_None	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	_X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_	AR is a member of the Leducq Foundation Scientific Advisory Committee. In this capacity, his primary role is to review grant applications and existing programs supported by the foundation.
11	Stock or stock options	_X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None	
13	Other financial or non- financial interests	_X_	AR is a scientific co-founder of a biotech start-up, LQTT, focused on developing small molecule therapies for Long QT Syndrome.

AR was supported by the National Institutes of Health (R01AG061034, R35HL155318). AR is a member of the Leducq Foundation Scientific Advisory Committee. In this capacity, his primary role is to review grant applications and existing programs supported by the foundation. AR is a scientific co-founder of a biotech start-up, LQTT, focused on developing small molecule therapies for Long QT Syndrome. Neither the Leducq Foundation nor LQTT were involved in AR's contributions to this manuscript.

Please place an "X" next to the following statement to indicate your agreement: